Parkinson's disease (PD) is the most common neurodegenerative motor disease. Pathologically, PD is characterized by Lewy body deposition and subsequent death of dopamine neurons in the substantia nigra pars compacta. PD also consistently features degeneration of the locus ceruleus, the main source of norepinephrine in the central nervous system. We have previously reported a mouse model of dopaminergic neurodegeneration based on reduced expression of the vesicular monoamine transporter (VMAT2 LO). To determine if reduced vesicular storage can also cause noradrenergic degeneration, we examined indices of damage to the catecholaminergic systems in brain and cardiac tissue of VMAT2 LO mice. At two months of age, neurochemical analyses revealed substantial reductions in striatal dopamine (94%), cortical dopamine (57%) and norepinephrine (54%), as well as cardiac norepinephrine (97%). These losses were accompanied by increased conversion of dopamine and norepinephrine to their deaminated metabolites. VMAT2 LO mice exhibited loss of noradrenergic innervation in the cortex, as determined by norepinephrine transporter immunoreactivity and 3 H-nisoxetine binding. Using unbiased stereological techniques, we observed progressive degeneration in the locus ceruleus that preceded degeneration of the substantia nigra pars compacta. In contrast, the ventral tegmental area, which is spared in human PD, remained unaffected. The coordinate loss of dopamine and norepinephrine neurons in VMAT2-LO mice parallels the pattern of neurodegeneration that occurs in human PD, and demonstrates that insufficient catecholamine storage can cause spontaneous degeneration in susceptible neurons, underscoring cytosolic catecholamine catabolism as a determinant of neuronal susceptibility in PD.
Introduction
Parkinson's disease (PD) is primarily characterized by motor deficits due to the loss of dopamine (DA) producing cells of the substantia nigra pars compacta (SNpc). However, PD is not restricted to the SNpc, as there is significant neurodegeneration in the locus ceruleus (LC), which is the primary source of brain norepinephrine (NE) . The degree and rate of LC loss have been reported to be similar to, if not greater than, that of the SNpc (Braak et al., 2003; Zarow et al., 2003) . Noradrenergic degeneration in PD has been implicated in parkinsonian motor deficits, neuropsychiatric symptoms (including depression, dementia, and psychosis), and sleep disturbances (Del Tredici and Braak, 2012; Gesi et al., 2000; Paulus and Jellinger, 1991) . Noradrenergic deficits in PD also extend into the periphery; cardiac sympathetic denervation occurs in most PD cases, and can manifest in the pre-motor phases of the disease (Goldstein et al., 2007) . Loss of sympathetic noradrenergic nerves in the myocardium may be as profound as the loss of dopaminergic terminals in the striatum (Amino et al., 2005) .
Each of these affected neuronal populations is of the catecholaminergic phenotype. The shared vulnerability of catecholamine neurons in PD can be ascribed in part to ongoing cytoplasmic neurotransmitter breakdown. Due to ongoing synthesis, plasmalemmal uptake, and vesicular leak, catecholamines are continuously present in the cytosol. The vesicular monoamine transporter 2 (Slc18a2; VMAT2) transports catecholamines from the cytosol into acidic synaptic vesicles, where they are stored for exocytic release. In noradrenergic neurons, NE is synthesized from DA via dopamine-β-hydroxylase inside the vesicle. Products of cytoplasmic catecholamine breakdown by autoxidation and enzymatic deamination are toxic (Burke et al., 2004; Caudle et al., 2007; Cubells et al., 1994) . This burden is characteristic of catecholamine neurons and may be a critical determinant of their susceptibility to neurotoxicity in PD (Caudle et al., 2008; Sulzer and Surmeier, 2012) .
Because VMAT2 is essential for vesicular catecholamine storage, its dysregulation can be deleterious to neuronal health. In mice, genetic ablation of VMAT2 is fatal, and while heterozygote knockout animals develop normally, they are more susceptible than wild-type mice to MPTP-and amphetamine-induced neurotoxicity (Guillot et al., 2008; Takahashi et al., 1997; Wang et al., 1997) . We previously reported that VMAT2 LO mice, which have a 95% reduction in VMAT2 expression, exhibit progressive nigrostriatal degeneration, highly dysregulated DA homeostasis, α-synuclein accumulation, L-DOPA-responsive motor deficits, and nonmotor features of PD, including depressive and anxiety-like behaviors (Caudle et al., 2007; Taylor et al., 2009) .
In this study, we tested whether VMAT2 LO mice exhibit noradrenergic degeneration. We assayed concentrations of DA, NE, and their metabolites in the cortex, striatum, and heart. Changes in noradrenergic innervation were assessed by immunochemistry for the norepinephrine transporter (NET) and by 3 H-nisoxetine binding. To quantify the extent of neuronal loss, we performed stereological analyses of catecholaminergic cell bodies in the LC and SNpc as well as in the ventral tegmental area (VTA), a dopaminergic nucleus less affected in PD.
Materials and Methods

Animals
Male and female VMAT2 LO mice were generated as previously described (Caudle et al., 2007; Taylor et al., 2009) . Briefly, the laboratory of Piers Emson (Mooslehner et al., 2001 ) generated a VMAT2 hypomorphic mouse on a C57BL/6 background. It was later revealed that the C57BL/6 subpopulation from which these mice were derived contained a spontaneous deletion spanning the α-synuclein gene locus (Specht and Schoepfer, 2001) . Through outbreeding to mice of the 129 strain, we reintroduced the deleted locus while maintaining the hypomorphic VMAT2 allele. These mice (VMAT2 LO) have been maintained on a C57/BL6 and 129 mixed background. The genotypes of all mice were confirmed by PCR of genomic DNA extracted from tail snips. This report represents the fourth set of data on VMAT2 LO mice with a normal α-synuclein background (Caudle et al., 2007; Guillot et al., 2008; Taylor et al., 2009) . All procedures were conducted in accordance with the National Institutes of Health Guide for Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at Emory University.
HPLC determination of catecholamines and metabolites
Mice were decapitated and their brains and hearts immediately dissected. From the brain, we collected the isocortex and ventral and dorsal striata between Bregma coordinates 2.0 mm and −1.9 mm. Tissues were frozen in liquid nitrogen, and catechol levels were measured by liquid chromatography with electrochemical detection after batch alumina extraction at the Clinical Neurochemistry Laboratory of the Clinical Neurocardiology Section in intramural NINDS (Goldstein et al., 2011b; Holmes et al., 1994) . Catechols of interest included the catecholamines, the catecholamine precursor L-DOPA, dihydroxyphenylacetic acid (DOPAC, the main neuronal metabolite of DA), and dihydroxyphenylglycol (DHPG, the main neuronal metabolite of NE). Mice of two months of age were used to determine catechol levels prior to the onset of neurodegeneration.
H-Nisoxetine binding to quantify norepinephrine transporter expression
3 H-Nisoxetine binding in brain homogenates was performed as previously described (Tejani-Butt, 1992) , with minor modifications. Briefly, mice were decapitated and their brains rapidly removed and dissected (described above). Cortical tissue was homogenized in 0.32 M sucrose, 10 mM HEPES at 1000 RPM with a Teflon homogenizer and Wheaton glass tube and centrifuged at 48,000×g. The resulting pellet was resuspended, homogenized, and centrifuged again. The final pellet was resuspended in 500 µl assay buffer (50 mM Tris, 300mM NaCl, 5mM KCl, pH 6.8). 200-400 µg (post-hoc determination) of sample was incubated in a 400 µL reaction mixture of 5 nM 3 H-nisoxetine (American Radiolabeled Chemicals, St. Louis, MO) for total binding, and with 10 µM desipramine (Sigma-Aldrich, St. Louis, MO) to determine nonspecific binding. Hearts were processed similarly, with the addition of first homogenizing cardiac tissue in ice cold 0.1M phosphate-buffered with a Tissue-Tearor tissue homogenizer (Bio Spec Products, Bartlesville, OK). Mice of 12 months of age were used to examine NET expression at the start of LC degeneration.
Immunohistochemical analysis of tyrosine hydroxylase and norepinephrine transporter
Tissue staining was completed as previously described (Caudle et al., 2006; Miller et al., 1999; Miller et al., 1997) . Briefly, we transcardially perfused phosphate buffered saline and 4% paraformaldehyde into mice. Tissue was removed and fixed in 4% paraformaldehyde for 24 h, followed by cryoprotectection in 30% sucrose for 48 h. The brains were sliced to a thickness of 40 µm on a freezing microtome (Microm, Kalamazoo, MI). For fluorescent immunohistochemistry, sections were incubated with mouse monoclonal anti-TH (1:1,000; Millipore) and rabbit polyclonal anti-VMAT2 (1:15,000, custom-made). Rabbit antisera was raised against the C-terminal VMAT2 peptide sequence CTQNNVQPYPVGDDEESESD (immunizations and sera collection performed by Covance, Princeton, NJ). Sections were then incubated with fluorophore-linked secondary antibodies against rabbit and mouse IgG, raised in goats (1:800, Life Technologies, Grand Island, NY). For DAB-peroxidase staining, free-floating sections were incubated with either rabbit polyclonal anti-tyrosine hydroxylase (TH) (1:2000; Millipore), or mouse monoclonal anti-NET (1:1,000, MAb Technologies, Stone Mountain, GA) overnight, followed by incubation in a biotinylated goat anti-rabbit secondary antibody (TH) or biotinylated goat anti-mouse (1:200; Jackson Immunoresearch) for 1 h at room temperature. NET detection was optimized with Citra citrate antigen retrieval kit (Biogenex, Fremont, CA). Visualization was performed using 3, 3´diaminobenzidine (DAB, St. Louis, MO) for 2 min at room temperature. After DAB, all sections were counterstained in hematoxylin, mounted on slides, dehydrated, and coverslipped using Permount (Fisher Scientific, Waltham, MA) with sections viewed using a light microscope (Olympus, San Jose, CA).
Stereological analysis of cell bodies
Stereological sampling (West et al., 1991) was performed using the Stereo Investigator software (MicroBrightField, Colchester, VT). Tissue staining was performed as described previously (McCormack et al., 2002; Reveron et al., 2002) . Whole brains were removed and processed for frozen sections as described above, and serially sectioned at 50 µm (final mounted thickness of 26 µm) for systematic analysis of randomly placed counting frames (size, 50 × 50 µm) on a counting grid (size of 120 × 160 µm) and sampled using an 22 µm optical dissector with 2 µm upper and lower guard zones. The boundaries of SNpc, LC, and VTA were outlined under magnification of the 4X objective as per the atlas of Paxinos and Franklin (2001) . Cells were counted with a 40X objective (1.3 numerical aperture) using an Eclipse e800 microscope (Nikon, Melville, NY). Guard zones of 2 µm ensured the exclusion of lost profiles on the top and bottom of the section sampled. A dopaminergic or noradrenergic neuron was defined as an in-focus TH-immunoreactive (TH-IR) cell body with a TH-negative nucleus within the counting frame. For the SNpc and VTA, every other section was processed for TH-IR, resulting in 20-25 sections sampled per mouse. For the LC, every section was stained for TH-IR and counterstained with hematoxylin, resulting in 15 sections sampled per mouse. The number of neurons in the SNpc, VTA, and LC was estimated using the optical fractionator method, which is unaffected by changes in the volume of reference of the structure sampled. Between 100 and 250 objects were counted-to generate the stereological estimates. Gundersen (m=1) coefficients of error were less than 0.1.
Statistics
Statistical analyses were performed using GraphPad Prism 5.0 (La Jolla, CA) Experiments with two factors (HPLC analysis of genotype and brain region, stereological analyses between genotypes) were analyzed by two-way ANOVA, followed by Bonferroni post-hoc tests for pairwise comparisons. One-factor experiments (HPLC of cardiac tissue, radioligand binding) were analyzed with t-tests for independent means. Results were reported as mean ± SEM, and statistical significance set at α=0.05. In figures, *p<0.05, **p<0.01, ***p<0.001.
Results
Immunohistochemical assessment of VMAT2 loss in SNpc and LC neurons
In this study, we sought to compare the effects of very low VMAT2 expression on the dopaminergic and noradrenergic systems. We thus evaluated VMAT2 expression in the SNpc and LC of VMAT2 LO mice using immunohistochemistry to confirm comparable reductions of the protein (Figure 1 ). Wildtype animals exhibited a cytosolic distribution of VMAT2 immunoreactivity in TH+ neurons of the SNpc and LC. Consistent with an earlier report (Mooslehner et al., 2001) , VMAT2 immunoreactivity in the SNpc of VMAT2 LO brains was essentially absent, save for trace somatic staining. In the LC, TH+ neurons were also nearly devoid of VMAT2 immunoreactivity, indicating very low Slc18a2 gene product in both regions.
VMAT2 LO mice have markedly reduced tissue catecholamine contents and increased relative deamination of catecholamines
Cortical and striatal tissues of 2-month old VMAT2 LO animals had reduced levels of both NE and DA (Figure 2A, B) . ANOVA revealed an effect of genotype on NE (F (1,18) =110.3, p<0.0001) and DA (F (1,18) =171.8, p<0.0001). In the cortex, we observed a 54% decrease in NE (wildtype: 268.8 ± 22.9 pg/mg, VMAT2 LO: 124.8 ± 11.81 pg/mg, p<0.001) and a tendency toward decrease in DA (wildtype: 557.5 ± 243.3 pg/mg, VMAT2 LO: 50.0 ± 9.9 pg/mg, p>0.05). In the striatum, we observed a 67% decrease in NE (wildtype: 284.2 ± 16.7 pg/mg, VMAT2 LO: 92.6 ± 6.9 pg/mg, p<0.001) and 94% reduction in DA (wildtype: 6125.8 ± 349.2, VMAT2 LO: 379.2 ± 70.7, p<0.001).
In both the cortex and striatum of 2-month old VMAT2 LO mice, we observed a genotypedependent increase in tissue DHPG:NE ratios ( Figure 2C ) (F (2,18) =23.73, p<0.0001). There were significant increases in both tissues (cortex: p<0.05, striatum: p<0.05). These mice also had genotype-dependent increase in DOPAC:DA ( Figure 2D ) (F (2,18) =47.4, p<0.0001) in the cortex (p<0.001) and striatum (p<0.01). L-DOPA levels were unchanged between genotypes (F (1,18) =0.02, p=0.9; striatum, wildtype: 20.3 ± 10.8, VMAT2 LO: 19.4 ± 4.4; cortex, wildtype: 12.8 ± 0.9, VMAT2 LO: 12.1 ± 1.9).
VMAT2 LO mice have decreased cortical expression of NET
We examined NET expression using immunohistochemistry in the somatomotor cortex of 12-month old wildtype and VMAT2 LO mice (Figure 3A, B) and observed a reduction in NET immunoreactivity. We quantified the reduction of NET expression in the cortex with 3 H-nisoxetine binding ( Figure 3C ), VMAT2 LO animals had a 20% reduction in 3 Hnisoxetine binding, compared to wild type (40.8 ± 2.2 vs. 49.5 ± 3.2 fmol/mg, p<0.05).
VMAT2 LO mice have age-related catecholaminergic degeneration in the LC and SNpc, but not in the VTA
At 12 months of age, VMAT2 LO mice did not differ from age-matched controls in TH expression or evidence of neurodegeneration, as measured by silver deposition, in the SNpc or LC (data not shown). At 18 months of age, the VMAT2 LO group had mildly reduced TH staining in the SNpc. The extent of abnormality progressed with age ( Figure 4 ). Larger reductions in TH staining were observed in the LC than the SNpc at 18, 24, and 30 months of age.
To quantify the extent of neuronal loss in the SNpc and LC in the VMAT2 LO mice, unbiased stereological cell counts were performed on TH− and hematoxylin-stained cells. In the SNpc, two-way ANOVA revealed an effect of genotype (F (1, 35) =44.14, p<0.001) and age (F (4,35) =120.6, p<0.0001) on the number of TH+ neurons ( Figure 5A) , although there was no interaction (F (4,35) =4.219, p=0.6). Hematoxylin+ cells followed the same pattern. At all ages, VMAT2 LO brains had fewer TH+ SNpc neurons than did wildtype littermates, though Bonferroni post-hoc tests did not reveal significance between genotypes at any single time point. Within genotypes, wildtype and VMAT2 LO mice underwent significant SNpc degeneration at 24 months of age, with respect to counts at 6 months (wildtype, 6 months: 5999 ± 176, wildtype, 24 months: 4039 ± 252, p<0.001; VMAT2 LO, 6 months: 5691 ± 286, 24 months: 3347 ± 331, p<0.001). At 30 months, wildtype mice (30 months: 3943 ± 159) had lost 34% of TH+ SNpc neurons, while VMAT2 LO mice (2614 ± 344) lost 54% of TH+ neurons with respect to the corresponding 6 month value for each groups.
Within the LC, neuronal survival was an effect of age (F (4,37) =44.14, p<0.0001) and genotype (F (1,37) =120.6, p<0.0001). There was an interaction between these factors (F (4,37) =4.219, p<0.01). Hematoxylin+ cell loss followed the same pattern as TH+ neuron loss. Bonferroni post-hoc tests revealed that degeneration of TH+ LC neurons was significantly greater in VMAT2 LO mice than in wildtype littermates beginning at 12 months ( When the VTA was examined for evidence of neuronal loss, no change was seen in wildtype or VMAT2 LO animals at 6 or 30 months of age ( Figure 6 ). At 6 months of age, wildtype and VMAT2 LO animals displayed similar numbers of TH-positive (wildtype: 4684 ± 544, VMAT2 LO: 4590 ± 159; p>0.05) and hematoxylin-positive neurons (wildtype: 6594 ± 694, VMAT LO: 6413 ± 236; p>0.05). Moreover, at 30 months of age, we observed no difference in the quantity of TH+ neurons in the VTA between wildtype and VMAT2 LO animals (wildtype: 4784 ± 429, VMAT2 LO: 4948 ± 349, p>0.05; hematoxylin-positive: wildtype: 7470 ± 813, VMAT2 LO: 7461 ± 567, p>0.05).
VMAT2 LO mice have reduced cardiac noradrenergic innervation
We assayed cardiac tissue for neurochemical aberrations in 2-month VMAT2 LO hearts (Figure 7 ). At this time point, we observed a 97% reduction in cardiac NE ( Figure 6A , wildtype: 469.1 ± 24.5 pg/mg, VMAT2 LO: 13.73 ± 13.6 pg/mg, p<0.0001). VMAT2 LO mice also showed reductions in cardiac DA ( Figure 7B , wildtype: 11.15 ± 1.1, VMAT2 LO: 4.03 ± 1.1, p<0.01). To ascertain if reduced catecholamine storage affected the integrity of sympathetic terminals over time, we performed 3 H-nisoxetine-binding in cardiomyocyte homogenates in 12-month old mice ( Figure 7C ). VMAT2 LO animals had substantially reduced (38%) 3 H-nisoxetine binding in contrast to their wildtype littermates (wildtype: 16.00 ± 1.64 fmol bound/mg tissue, VMAT2 LO: 10.09 ± 0.73, p<0.05).
Discussion
Our findings demonstrate that dramatically reduced VMAT2 expression augments the agerelated loss of noradrenergic neurons in the locus ceruleus. We observed that genetic VMAT2 deficiency in vivo drives catecholamine depletion in the central nervous system and heart and increases relative cytosolic catecholamine catabolism by MAO. These findings in transgenic mice bear particular relevance to the pathology of PD where vesicular function may be compromised as a consequence of exogenous insult (Corrigan et al., 1998; Hatcher-Martin et al., 2012) , genetic polymorphism (Brighina et al., 2013; Glatt et al., 2006; Uhl et al., 2000) , or a cytosolic milieu that favors an oxidative state, especially with mitochondrial dysfunction (Schapira, 2011) and aging (Cruz-Muros et al., 2008) . Indeed, post-mortem analysis of putamen tissue has revealed that PD patients exhibit neurochemical indices of reduced vesicular uptake of DA and buildup of DOPAL, a toxic MAO metabolite of DA (Goldstein et al., 2013) .
In young (2 months) VMAT2 LO mice, we observed baseline deficits in striatal and cortical NE and DA, a direct result of insufficient vesicular catecholamine storage (Figure 2) . Cytosolic catecholamines are subject to enzymatic deamination and autoxidation. Cytosolic autoxidation of catecholamines and their metabolites generates reactive quinone species and other oxidative metabolites (Sulzer and Zecca, 1999) . We previously reported that the striata of VMAT2 LO mice showed elevated indices of cytosolic DA oxidation, in the form of cysteinyl-catechol adducts, as well as relatively increased generation of DOPAC (Caudle et al., 2007) . Here, we have additionally reported that the cortices and striata of VMAT2 LO mice have increased conversion of NE to DHPG. These neurochemical aberrations are life-long in VMAT2 LO mice, and set the stage for the eventual age-related neuronal loss we observed in the LC and SNpc ( Figure 5 ).
We observed that the LC of VMAT2 LO mice degenerated earlier (12 months) and to a greater extent than did the SNpc (24 months) ( Figure 5) . Clinically, the LC consistently degenerates in PD patients (Chan-Palay and Asan, 1989; Del Tredici and Braak, 2012; Forno, 1996) with severe decreases (as great as 78%) in neuronal number, possibly contributing to the neuropsychiatric symptoms of PD (Mann, 1983; Zarow et al., 2003) . It has been theorized that the trophic signaling from the LC compensates for the debilitating effects of progressive nigrostriatal death and delays the onset of clinical signs until greater DA depletion has occurred (Antelman and Caggiula, 1977) . Moreover, it has been demonstrated that noradrenergic neurons of the LC are responsible for dopaminergic signaling within the mouse hippocampus (Smith and Greene, 2012) ; this may occur elsewhere, especially in a setting of dopaminergic degeneration. The relationship between noradrenergic and dopaminergic degeneration established in this study suggests that NE loss could play a significant role in parkinsonian manifestations ranging from olfactory disturbances observed at 4 months of age in VMAT2 LO mice to depressive-like behaviors seen at 12-15 months (Taylor et al., 2009 ). Degeneration of the noradrenergic LC and other non-dopaminergic centers have been inferred in post-mortem PD brains. These monoaminergic centers are not directly related to the motor phenotype, yet contribute significantly to disease progression (Braak et al., 2003; Del Tredici and Braak, 2012; Gesi et al., 2000; Halliday et al., 1990; Murai et al., 2001; Rommelfanger and Weinshenker, 2007) . Braak and colleagues propose that PD begins in the dorsal motor and olfactory nuclei of the brainstem and progresses topographically through susceptible regions (Braak et al., 2002; Braak et al., 2003) . Motor disturbances do not present clinically until approximately 70-80% of striatal dopaminergic terminals have been lost; however, other non-motor symptoms are evident before the onset of motor disturbances. In the VMAT2 LO mice, it has been observed that the major motor deficits (e.g. shortened stride length) do not appear until 28 months of age, coinciding with the most severe SNpc cell loss ( Figure 5A) (Taylor et al., 2011) . The preceding phenotypes seen in the VMAT2 LO mice may be attributed to extradopaminergic changes (Taylor et al., 2009 ).
An intriguing finding in this study is that while the LC and SNpc of VMAT2 LO mice degenerated, the dopaminergic VTA remained unaffected ( Figure 6 ). The VTA is less affected or spared in human PD and is resistant to degeneration in toxicant models (Dauer and Przedborski, 2003; German et al., 1992) . Physiological differences between the VTA and SNpc may explain their disparate susceptibilities to neurotoxicity. The VTA is phenotypically distinct from the neighboring SNpc in its expression of calbindin, a calcium buffering protein, and unlike the SNpc it is not reliant on calcium influx for autonomous pacemaking (Surmeier et al., 2005) . It has been demonstrated that cytosolic calcium increases conversion of L-DOPA to DA by amino acid decarboxylase, which occurs to a greater extent in SNpc neurons than in the VTA; this mechanism was shown to be responsible for the selective susceptibility of the SNpc over the VTA to L-DOPA-induced neurotoxicity in mice (Mosharov et al., 2009; Surmeier, 2009 ). PD also affects the autonomic nervous system. Cardiac sympathetic denervation is a common comorbid event in the pathophysiology of PD, with 30% of patients meeting the diagnostic criteria for orthostatic hypotension (Velseboer et al., 2011) . Loss of VMAT2 function either contributes to, or is associated with, this pathology. PD patients with orthostatic hypotension exhibit reduced VMAT2 function as measured by peripheral vesicular sequestration of 18 F-labeled catecholamine analogs (Goldstein et al., 2011a) . By design, VMAT2 LO mice are unable to sequester cytosolic catecholamines and consequently bear a striking 97% reduction in cardiac NE is seen at 2 months ( Figure 7A ). The magnitude of cardiac NE loss in contrast to the more modest reductions in the striatum and cortex may reflect variability between neuron types with respect to synthesis and release patterns, extraneuronal milieu, and expression of catecholamine metabolizing enzymes. Patients with cardiac sympathetic denervation have reduced binding of high-affinity PET ligands for NET in heart (Dae, 1994; Goldstein, 2003) . Similarly, hearts of 12-month VMAT2 LO mice have substantial (40%) reduction of NET, revealed by 3 H-nisoxetine binding ( Figure 7C ).
While the focus of this work examined the neurotoxic effects of cytoplasmic catecholamines, we should not overlook the role of α-synuclein in this pathology. VMAT2 LO mice do not undergo spontaneous neurodegeneration in the absence of endogenous αsynuclein (Colebrooke et al., 2006) . Similarly, VMAT2 deficiency potentiates the toxic effects of lentiviral α-synuclein overexpression in mice (Ulusoy et al., 2012) . Lastly, knockout of α-synuclein dramatically abrogates the effects of L-DOPA-and calciuminduced neurotoxicity in midbrain DA neurons (Mosharov et al., 2009) . This interplay is supported by in vitro experiments which have demonstrated that products of cytoplasmic dopamine breakdown oligomerize α-synuclein (Burke et al., 2008) and stabilize subsequent protofibril formation (Conway et al., 2001) ; it is hypothesized that this mechanism could drive Lewy body pathology in vivo (Sulzer, 2001) . Collectively, these findings indicate that cytoplasmic catecholamine catabolism and α-synuclein may synergistically participate in PD pathogenesis.
Conclusions
Our findings in VMAT2 LO mice demonstrate that insufficient catecholamine storage is capable of driving noradrenergic neurodegeneration in an in vivo setting. Despite the deleterious effects of reduced VMAT2 expression on the SNpc and LC, the VTA remained unaffected, likely due to physiological differences that make this region resilient in animal models and human PD. The combination of LC and SNpc degeneration and the absence of VTA degeneration is strikingly consistent with human PD and underscores the importance of proper catecholamine sequestration to neuronal health. VMAT2 activity, with its role in catecholamine homeostasis, may be a critical determinant in noradrenergic and dopaminergic susceptibility to neurotoxicity. acquisition of HPLC data. We would like to thank Dr. Alison Bernstein for generating and characterizing the VMAT2 antibody. A and B, Immunohistochemical labeling in the somatomotor cortex. At 12 months of age, VMAT2 LO mice showed a reduction in NET immunoreactivity throughout the cortex, compared to wildtype (representative images of somatomotor area shown at 20× magnification). C, 3 H-nisoxetine-binding was performed to quantify changes in NET abundance. C, There was a reduction (20%) in nisoxetine binding sites in 12-month VMAT2 LO cortices (n=6). Results represent the mean ± SEM for 6 animals per genotype at each age. *p<0.05.
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Figure 4. VMAT2 LO animals undergo progressive catecholaminergic cell loss
Immunohistochemical analysis of tyrosine hydroxylase in locus ceruleus of aged VMAT2 LO mice. TH immunoreactivity was substantially reduced in VMAT2 LO mice at 18, 24, and 30 months of age, preceding loss observed in the substantia nigra. Analysis was performed on 5 animals per genotype at each age. Representative sections are shown. Scale bars, 500 µm.
Figure 5. Quantitative analysis of catecholaminergic cell loss reveals degeneration of LC precedes that of SNpc
TH and hematoxylin cell counts in the SNpc and LC of 6, 12 18, 24, and 30 month wildtype and VMAT2 LO mice. A, Significant reductions in TH cell counts in the SNpc were observed beginning at 24 months in wildtype and VMAT2 LO mice, with VMAT2 LO mice having fewer TH cells overall. B, Furthermore, a similar age-dependent reduction in hematoxylin cells in the SNpc was seen in wildtype and VMAT2 LO mice. C, Wildtype and VMAT2 LO mice underwent progressive loss of TH cells in the LC, with VMAT2 LO mice having accelerated loss compared to wildtype, beginning at 12 months of age. D, A significant reduction was also seen in hematoxylin cells in the LC at 18, 24, and 30 months of age in VMAT2 LO mice compared to wildtype in the LC. Results represent the mean ± SEM for 5 animals per genotype at each age. *p<0.05, **p<0.01; ***p<0.001 (with respect to 6 month mice within genotype) †<0.05, ‡<0.001 (between genotypes). 
